KALA - Kala Pharmaceuticals GAAP EPS of $19.25 revenue of $0.42M
- Kala Pharmaceuticals press release ( NASDAQ: KALA ): Q3 GAAP EPS of $19.25.
- Revenue of $0.42M (-86.3% Y/Y).
- As of September 30, 2022, Kala had cash and cash equivalents of $52.4 million, compared to $44.6 million of cash and cash equivalents as of June 30, 2022.
For further details see:
Kala Pharmaceuticals GAAP EPS of $19.25, revenue of $0.42M